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Abstract
Background: Bile acids (BAs) are synthesized by the liver and modified by gut bacteria, and may play 
an intermediary role between the gut microbiome and liver in promoting fibrosis in non-alcoholic 
fatty liver disease (NAFLD). We investigated the associations between serum and faecal BAs, gut 
microbiome and fibrosis in patients with and without NAFLD and examined the impact of diet and 
alcohol consumption on these relationships. 
Methods: Adult patients (n=122) underwent liver biopsy and BAs characterization by 
high-performance liquid chromatography/mass spectrometry. Gut microbiome composition was 
analysed using next-generation 16S rRNA sequencing. Diet and alcohol intake were determined by 
3-day food diary. 
Results: Serum and faecal BA concentrations increased progressively between non-NAFLD controls 
(n=55), NAFLD patients with no/mild fibrosis (F0-2, n=58), and NAFLD with advanced fibrosis (F3/4, 
n=9). Progressive increases in serum BAs were driven by primary conjugated BA’s including 
glycocholic acid [GCA] and secondary conjugated BA’s. In contrast, faecal BA increase was driven by 
secondary unconjugated BA’s (predominately deoxycholic acid [DCA]). Serum GCA levels and faecal 
DCA levels correlated with the abundance of Bacteroidaceae and Lachnospiraceae, and stool 
secondary BAs with an unclassifiable family of the order Bacteroidales (Bacteroidales;other). These 
bacterial taxa were also associated with advanced fibrosis. Modest alcohol consumption was 
positively correlated with faecal DCA levels and relative abundance of Lachnospiracaea and 
Bacteroidales;other.
Conclusions: Higher serum and faecal BA levels are associated with advanced fibrosis in NAFLD. 
Specific gut bacteria link alterations in BA profiles and advanced fibrosis, and may be influenced by 
low level alcohol consumption.
Keywords: Non-alcoholic steatohepatitis, fibrosis, microbiome, deoxycholic acid, diet
Lay Summary:
 Specific gut bacteria link alterations in BA profiles and advanced fibrosis, and may be 
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 Faecal levels of toxic deoxycholic acid [DCA] and its serum metabolite (glycodeoxycholic acid) 
are increased in patients with NAFLD and advanced (F3/4) fibrosis. 
 Specific gut microbial taxa (Lachnospiraceae, Bacteroidaceae, Bacteroidales;other) associated 
with advanced fibrosis and with serum and faecal BA levels. 
 Low-level alcohol consumption correlates with the relative abundance of gut 
Lachnospiraceae, Bacteroidales;other and faecal DCA levels. 
Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined by the presence of hepatic lipid in the absence of 
excess alcohol consumption and is typically associated with obesity and insulin resistance.(1) The 
prognosis of patients with NAFLD is determined principally by their degree of liver fibrosis, and 
patients with advanced liver fibrosis are at highest risk of developing cirrhosis and hepatocellular 
carcinoma.(2) The gut microbiome and the entero-hepatic circulation of bile acids (BA), have been 
increasingly implicated in the genesis of liver injury and fibrosis in patients with NAFLD.(3) 
Collectively, BA’s are steroid molecules originating from the metabolism of cholesterol and may be 
classified as primary (from the liver) or secondary (derived from gut microbial metabolism of primary 
BA’s). BA’s are important signalling molecules involved in glucose, lipid and energy metabolism.(4) In 
humans, serum levels of BA’s correlate with levels of insulin resistance, whereas BA sequestrants 
alter lipid levels and improve serum glucose.(5,6) BA’s may act on farnesoid X receptors (FXR) in the 
gut or liver to influence hepatic lipid metabolism and injury, or may be directly hepatotoxic in the 
case of deoxycholic acid (DCA).(7-9) Among patients with non-alcoholic steatohepatitis (NASH), the 
synthetic BA derivative obeticholic acid significantly improves liver fibrosis.(10) Therefore 
understanding the relationship between BA’s within the gut and the systemic circulation, may 
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The generation of secondary BA’s occurs via bacterial metabolism of primary BA’s within the 
intestine. Thus the composition of the gut microbiome has a significant influence on composition of 
the BA pool. Consequently, alteration of the gut microbiome by antibiotics or diet leads to change in 
BA profiles, and reductions in NAFLD and liver injury in animal models.(11,12) As yet, it is unknown 
whether diet plays a similar role in altering the gut microbiome and BA composition in NAFLD 
patients.
To date, it remains unresolved whether altered BA composition associated with gut dysbiosis is 
involved in the genesis of liver fibrosis in NAFLD patients. Studies examining serum BA levels have 
been conflicting whether secondary BA levels are increased or decreased in NASH.(13-15) Moreover, 
others have suggested altered BA levels are related to insulin resistance rather than NASH.(5) 
Furthermore, studies examining BA levels in NAFLD have focused primarily on their association with 
NASH and not fibrosis, and have examined just one compartment of BA metabolism (gut or serum). 
In addition, whether gut dysbiosis is associated with altered BA profiles and dietary composition in 
NAFLD patients is not well characterized. 
We sought to describe the association between gut and serum BA profiles, NAFLD and fibrosis, 
in a large cohort of patients with a spectrum of liver histology. We hypothesized that BA profiles 
would differ according to the presence of NAFLD and advanced fibrosis, supporting a role of BA in 
the pathogenesis of NAFLD and fibrosis. Secondly, we aimed to investigate the relationship between 
BA profiles and the gut microbiome. We hypothesized that gut bacteria involved in BA metabolism 
would associate with faecal BA levels and that these relationships would be altered according to the 
presence of fibrosis. Lastly, we sought to assess the influence of diet and alcohol on gut microbiome 
and BA profiles in relation to liver fibrosis, hypothesizing that they may shape a microbiome and BA 
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Methods
Subjects:  Adults undergoing liver biopsy as part of clinical care or during bariatric surgery were 
recruited from three centres located in Perth, Western Australia: the Hepatology Department and 
Department of Surgery (Sir Charles Gairdner Hospital) and Obesity Surgery WA (Murdoch Hospital). 
Exclusion criteria included age <20 or >65 years, weekly alcohol consumption >140 grams for 
females, and >210 grams for males, current use of antibiotics or immunosuppressants, major 
gastro-intestinal tract surgery, active gastrointestinal disease, secondary causes of NAFLD, 
concomitant liver disease, poorly controlled diabetes (HbA1c>8.5%) and contra-indication to liver 
biopsy.
Subjects were grouped into 3 categories based upon their liver histology: 1) controls with normal 
liver histology with <5% hepatic steatosis, 2) NAFLD with no/minimal fibrosis (F0-2) and (3) NAFLD 
with advanced fibrosis (F3,4).  Controls were patients undergoing bariatric surgery and no evidence 
of liver disease on liver biopsy.
The study was approved by the human research ethics committees of Sir Charles Gairdner and 
Group and Murdoch Hospitals with all subjects providing written informed consent.  A total of 122 
patients were analysed of which 122 had faecal BAs and gut microbiome profiles and 120 with 
serum BA profiles.
Clinical Assessment:  All subjects underwent a standardized assessment including a questionnaire 
regarding alcohol intake(16), medications and past medical history. Anthropometric measures were 
taken using standardized methods. Dietary data including quantification of alcohol consumption was 
available in 87 participants and was assessed by completion of a 3-day food record and analysed 
using FoodWorks®7 Pro (Xyris Software, Brisbane, Australia).
Biospecimens:  Fasting serum was collected on the day of liver biopsy and was analysed for 
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laboratory (PathWest, Nedlands, WA). Liver biopsies were stained with hematoxylin-eosin and 
trichrome stains. Faecal specimens were collected within two weeks of the liver biopsy according to 
the Human Microbiome Project sampling protocol(17) before being stored at minus 80°C.
Liver Injury Assessment:  Biopsies were scored according to the NASH CRN scoring system(18) by 
an expert liver pathologist (BdB). 
Serum and Faecal Bile Acid Characterization:  Sample extraction and preparation was adapted 
from Humbert et al(19), and is outlined in the Supplementary Methods. Bile acid quantification was 
performed using Nextera Ultraperformance Liquid Chromotography (SHIMADZU, Kyoto, Japan) 
system used in combination with a Q-TRAP 5500 Mass Spectrometer (AB SCIEX, Toronto, Canada) 
with Analyst Software 1.6.2. 
Microbiome Characterisation:  Faecal bacterial DNA was extracted and sequenced using the MiSeq 
Illumina platform (see supplementary methods). Following demultiplexing and initial sequence 
quality control assessments, samples were analyzed using the QIIME pipeline.(20) Initially reads 
were grouped into operational taxonomic units at different distance thresholds using the Uclust 
algorithm. A representative sequence from each OTU was aligned against the Greengenes reference 
alignment as implemented in QIIME for phylogenetic identification.
Statistical Analysis:  Clinical and BA profiles are described using means with standard deviations 
(±SD) or medians with interquartile ranges, according to their distribution.  Bile acids representing 
>5% of the total BA pool are presented.(21) Differences between groups (non-NAFLD, NAFLD with 
F0-2 and NAFLD with F3/4) in clinical parameters or individual BA’s were tested using Chi-squared 
test for categorical data and Mann-Whitney U test for continuous data. Differences in BA 
composition between groups was assessed using Jonckheere-Terpstra test with post-hoc pairwise 
comparisons with Bonferroni correction. The association between clinical and histological factors 
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individual BA’s and advanced fibrosis was examined using multivariate logistic regression following 
adjustment with clinical factors found to be associated with advanced fibrosis on univariate logistic 
regression. Correlation between BA profiles and individual microbial taxa was assessed using 
spearman correlation with Bonferroni adjustment for multiple testing. Analysis was performed using 
SPSS v24 (IBM, Armonk New York).
Results
Patient Characteristics  
Overall the cohort (n=122) was middle aged and predominately female (81%). The majority were 
obese with 28% having type 2 diabetes and 37% having a history of hypertension.  Over half of the 
cohort had NAFLD (55%), with 13% of these having advanced (F3/4) hepatic fibrosis. The percentage 
of NAFLD patients with F0, F1, F2, F3 and F4 fibrosis was 46%, 34%, 6%, 9% and 4.5% respectively. 
Age, liver enzymes and metabolic features increased progressively across groups (Table 1). Body 
mass index (BMI) was evenly distributed between groups.
Associations Between Serum Bile Acids and Advanced NAFLD  
A progressive increase in total serum BA’s was seen from controls, F0-2 NAFLD to F3/4 NAFLD 
(Figure 1, Supplementary Table 1). The largest contribution was related to increased concentrations 
of primary conjugated BA’s and secondary conjugated BA’s (Figure 1A). The proportion of primary 
conjugated BAs within the total primary BA pool also increased significantly (p<0.05) between 
groups (Figure 2).  Specifically, the proportion of glycocholic acid (GCA) and glycodeoxycholic acid 
(GDCA) also increased as a proportion of total primary and secondary BAs respectively (p<0.05 for all 
comparison).  
Total serum BA levels were associated with serum ALT and GGT and histological features of 
steatosis, inflammation, ballooning and fibrosis (Supplementary Table 2) but not age, sex or 
metabolic factors including insulin resistance (HOMA-IR). Serum primary conjugated, secondary 
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cohort (Table 2), however following adjustment for clinical factors also associated with advanced 
fibrosis (outlined in supplementary table 3), only primary (including GCA and glycochenodeoxycholic 
acid [GCDCA]) and secondary conjugated BAs (including GDCA) remained significant. The association 
with total primary conjugated BA’s and GCDCA remained significant after additional adjustment for 
gender and HOMA-IR (data not shown).
Associations Between Faecal Bile Acids and Advanced NAFLD
A progressive increase in secondary unconjugated BAs were noted between groups (Figure 1B, 
Supplementary Table 4) with specific increases in deoxycholic acid (DCA) and lithocholic acid (LC). 
Similarly, levels of secondary unconjugated BAs, DCA and LC were predictive of advanced fibrosis 
(Table 3). The association between faecal BA’s and advanced fibrosis remained significant following 
additional adjustment for gender and insulin resistance (HOMA-IR, data not shown). There was no 
difference in the proportion of unconjugated BAs, DCA or LC within the total secondary BA pool 
between groups (data not shown). 
Association Between Gut Microbiome and Advanced Liver Fibrosis
Alpha diversity was significantly lower in the F3/4 group (Chao1 Index 275.0  72.4) compared to 
controls and NAFLD F0-2 subjects (347.9  72.5, p=0.012 and 349.6  65.1, p=0.003 respectively). 
Between group differences in diversity were also noted [Analysis of similiarities (ANOISM) p=0.007 
(unweighted); p=0.049 (weighted) and ADONIS (PERMANOVA) p=0.002 (unweighted); p=0.01 
(weighted)].
The relative abundance of microbial taxa differed significantly between groups, with a greater 
proportion of Firmicutes, Proteobacteria and Actinobacteria but fewer Bacteroidetes in NAFLD F3/4 
patients (Supplementary Figure 1).  At the family level, (Figure 3) a greater abundance of 
Actinomycetaceae and Lachnospiraceae observed in F3/4 patients, but lower abundance of 
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p<0.05, Bonferroni corrected). No significant associations were noted at the genus level following 
Bonferroni correction.   
Association Between Gut Microbiome and Serum and Faecal Bile Acids
Significant correlations were observed between the abundance of gut microbial families and faecal 
BA concentrations (Figure 4). Specifically, faecal secondary unconjugated BA’s and total secondary 
BA’s correlated with taxa that were also associated with F3/4 fibrosis, namely Bacteroidaceae, 
Bacteroidales;other and Lachnospiraceae. Faecal DCA levels also correlated negatively with 
Bacteroidaceae and positively with Lachnospiraceae.  
Significant correlations were also observed between the abundance of gut microbial taxa and serum 
BA concentrations, which were similar to the associations seen with faecal BA levels (Figure 4). 
Notably, serum GCA was positively correlated with Lachnospiraceae and negatively with 
Bacteroidaceae and Rickenellaceae.
Associations Between Diet and Alcohol Intake and Gut Microbiome
A significant positive correlation was seen between average daily alcohol consumption and the 
relative abundance of Bacteroidales;other whereas a negative correlation was observed with 
Lachnospiraceae (Table 4). In addition, alcohol consumers (n=40) compared with non-alcohol 
consumers (n=49) had a higher mean (standard deviation) abundance of Bacteroidales;other [1.6 
(2.3) versus 0.6 (0.8), p<0.05 Bonferonni corrected]. Lachnospiraceae was lower in alcohol 
consumers [22.5 (10.4) versus 28.6 (14.4), p-0.045], however this lost statistical significance 
following Bonferonni correction.
The family Barnesiellaceae was correlated with total fat intake (spearman rho 0.22, p=0.04), 
percentage of energy from fat (spearman rho 0.24, p=0.02) and saturated fat (spearman rho 0.21, 
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No additional associations between taxa and dietary intake of starch, fibre or protein were observed 
(data not shown).
Associations Between Diet and Alcohol Intake and Bile Acids
A significant inverse association was noted with total faecal BA (spearman rho -0.23, p=0.03) and 
faecal DCA levels (Spearman rho -0.20, p=0.05).  No association with alcohol consumption and 
serum BA’s were noted. In addition, no significant association between diet and serum or faecal BA 
levels were noted (supplementary tables 5 and 6).
Discussion
Our findings support the role of the gut-liver axis as an important pathway in the pathogenesis of 
liver fibrosis in humans with NAFLD. In this large series of patients with liver histology, we found 
levels of primary and secondary conjugated serum BAs and secondary conjugated faecal BAs were 
higher among patients with advanced fibrosis, and were also associated with microbial taxa which in 
turn also associated with advanced liver fibrosis. Despite the relatively small number of patients with 
F3/4 fibrosis, significant differences in BA and microbiome profiles were observed between groups, 
highlighting the magnitude of differentiation that occurs with different fibrosis levels in NAFLD.  
Specifically, serum GCA and GCDA increased as a proportion of the total primary and secondary BA 
pools respectively, and were independently associated with advanced liver fibrosis. Within the gut, 
faecal DCA was the dominant BA that increased in the presence of NAFLD and was also predictive of 
advanced fibrosis. Specific gut microbial taxa (Lachnospiraceae; Bacteroidales;other; Bacteroidaceae) 
were correlated with faecal BA levels (including DCA) and also had altered abundance in patients 
with advanced fibrosis. Lastly, we found that alcohol ingestion at modest amounts, was inversely 
associated with Lachnospiraceae and Bacteroidales;other and faecal DCA levels. This suggests that a 
complex and potentially pathogenic interaction between BA metabolism and gut microbiome occurs 
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Significance of Altered BA metabolism in Advanced NAFLD
It is likely that the increased gut BA levels seen in NAFLD F3/4 subjects altered the gut microbial 
composition, with high levels favouring proliferation of gram positive bacteria such as 
Lachnospiraceae but reducing Bacteroidetes (gram negative) which includes the families 
Bacteroidales, Rikenellaceae, Bacteroideaceae and Barnesiellaceae.(22-24)  Notably in 
decompensated cirrhosis where faecal BA levels fall, gut gram positives including Lachnospiraceae 
are lower and the abundance of gram negatives (including Enterobacteriaceae) are higher.(25) The 
gut microbiome may in turn, influence secondary BA levels via bacterial enzymes including 
7α-dehydroxylase which converts CA to DCA and is present in the Clostridium XIVa cluster, a 
member of the Lachnospiraceae family.(22,26,27)  In our cohort, faecal DCA was associated with 
the abundance of Lachnospiraceae and advanced liver fibrosis. Serum G-DCA levels, which represent 
the hepatic conjugated product of gut DCA, were also increased and associated with advanced 
fibrosis, consistent with increased liver exposure to gut-derived DCA. In animal models, DCA is 
cytotoxic and increases gut permeability potentially increasing the exposure of the liver to gut 
derived toxins (eg bacterial lipopolysaccharide), which promotes liver injury in animal models of 
NAFLD.(28) Gut derived DCA also promotes a senescence-associated secretory phenotype in hepatic 
stellate cells in obesity related fatty liver in mice, which in turn secretes inflammatory and 
tumour-promoting factors, facilitating NASH and HCC development.(29) Thus, our data supports the 
hypothesis that an interplay between increased BAs and gut microbiome composition favours the 
production of increased hepato-toxic DCA among NAFLD patients with advanced liver fibrosis. 
Our study extends earlier reports that serum BAs increase among patients with NASH (13,14) to 
demonstrate that levels increase significantly among patients with advanced liver fibrosis and that 
this relationship was independent of insulin resistance. Similar to our findings, Caussy and colleagues 
recently demonstrated serum BA levels as well as the proportion of conjugated primary BAs, also 
increase with increasing fibrosis in patients with NAFLD.(30) We also demonstrate that serum levels 
(as opposed to proportions) of BA species change significantly with fibrosis in NAFLD.  In addition, 
we demonstrate that faecal BAs, which are representative of 80% of the total BA pool (in contrast to 
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and further again in those with advanced hepatic fibrosis.  Thus the combination of increased 
faecal BA loss in combination with increased serum BA is strongly suggestive of increased hepatic BA 
synthesis. This supports previous findings in children where increased hepatic gene expression of 
CYP7A1 (the rate limiting enzyme in BA synthesis) was observed in obese patients with NASH 
compared with lean healthy controls.(13)
Influence of Diet and Alcohol
Animal studies suggest that a high fat diet may drive increased BA synthesis with subsequent 
alterations in the gut microbiome composition favoring increased production of secondary BAs such 
as DCA.(31) Human studies have been conflicting as to the impact of dietary fat on BA 
profiles.(32,33) We did not find an association between dietary fat intake and BA profiles though 
found a modest correlation with Barnsiellaceae which correlated with total faecal secondary BA 
levels. However, we found that low level alcohol consumption, at levels of less than three standard 
drinks a day, was associated with favorable microbial taxa and had an inverse association with 
unfavourable microbial taxa and faecal BA species. This raises the possibility that low-level alcohol 
impacts on gut microbiome-BA interactions to produce an environment that is not injurious to the 
liver. The association between alcohol and liver injury in NAFLD is controversial, with some but not 
all studies demonstrating low-level alcohol consumption being associated with reduced fibrosis 
levels(16).  
The reduced faecal BA levels seen with alcohol consumption may reflect reduced faecal 
excretion due to increased intestinal BA uptake or reduced production of secondary BA (DCA) due to 
alcohol related reduction in dehydroxylating bacteria such as Lachnospiraceae(34,35). Notably other 
studies have demonstrated increased faecal DCA levels in alcoholic cirrhosis, however this is 
presumably related to the higher doses of alcohol ingested and the advanced state of liver 
disease(36).  
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We found specific associations between gut microbial composition and NAFLD and advanced fibrosis 
with increased Proteobacteria, Firmicutes and Actinobacteria, but reduced Bacteroidetes noted at 
the phylum level. At the family level, reduced Bacteroidaceae, an unclassifiable family of the order 
Bacteroidales (Bacteroidales;other) but increased Actinomycetaceae and Lachnospiraceae were 
observed in F3/4 patients.  Similar to our findings, a consistent association between increased 
Proteobacteria and NAFLD has been reported previously(37-39), whereas associations between 
other phylum and NAFLD and fibrosis have been discordant.(39) For example, both increased and 
decreased Bacteroides have been reported to be associated with advanced fibrosis/cirrhosis using 
metagenomic methods.(38,40) Reduced Bacteroidaceae has previously been found to be associated 
with liver cirrhosis, whereas in contrast to our findings, reduced Lachnospiraceae has been 
documented to be associated with cirrhosis although this may be related to falling faecal BA levels in 
the setting of decompensation.(35,39) The associations between Actinomycetaceae have not been 
previously reported to our knowledge and need to be confirmed in larger cohorts. Different 
methods of microbiome characterization, bio-informatics and analysis as well as the influence of 
other environmental (eg diet) and patient factors (eg obesity) are all likley contribute to the 
conflicting findings in the literature. 
Study Limitations
Whilst the size of the cohort compares favourably with other studies examining BA and gut 
microbiome profiles, there were only nine subjects in the group with advanced fibrosis limiting our 
ability to detect associations at the genus level. Despite statistically significant differences being 
found at other taxonomic levels, we acknowledge that the generalizability may be limited and 
replication in a different cohort is required. This is particularly relevant given the multiple 
comparisons performed in our study. Lastly, longitudinal studies characterizing the change in gut 
microbiome, BA levels and liver histology in response to diet are required before the clinical 
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In this prospective study of adults matched for BMI, we demonstrate that BA metabolism is 
increasingly altered in the presence of NAFLD and subsequent advanced fibrosis. Serum and faecal 
BA levels progressively increase and become enriched in injurious BAs. In parallel, the gut 
microbiome profile is enriched with bacteria capable of increasing secondary BA levels, in particular 
DCA which could promote hepatic inflammation. Lastly, low level alcohol consumption was inversely 
associated with deleterious BA and gut microbiome profiles. This suggests a significant role of the 
gut environment in the development of NAFLD and liver fibrosis and supports the concept of 
modification of the gut microbiome and BA pool as therapeutic strategy. 
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N=55 N=58 N=9
Age (years) 45.6 ± 10.0 49.5 ± 10.2 51.6 ± 11.2 0.075
Male, n (%) 5 (9.1) 18 (31.0) 3 (33.3) 0.008
BMI, kg/m2 42.7 ± 8.9 42.2 ± 8.9 39.9 ± 8.8 0.694
Waist circumference, cm 118 ± 18 124 ± 17 125 ± 20 0.170
Mean alcohol (gm/week) 3.7 (9.5) 3.6 (6.2) 3.0 (9.2) 0.997
Obese, n (%) 52 (94%) 53 (95%) 8 (100%) 0.978
Diabetes, n (%) 5 (9.1) 21 (36.8) 7 (87.5) < 0.001
Hypertension, n (%) 16 (29.1) 25 (45.5) 4 (50.0) 0.146
SBP, mmHg 129 ± 17 132 ± 15 133 ± 14 0.525
DBP, mmHg 81 ± 11 78 ± 8 75 ± 13 0.178
Bilirubin (mmol/l) 8.9 ± 4.1 9.2 ± 5.9 9.2 ± 7.9 0.955
ALT (IU/l) 30 ± 15 48 ± 44 61 ± 84 0.016
AST (IU/l) 25 ± 29 28 ± 15 41 ± 16 0.247
ALP (IU/l) 86 ± 26 87 ± 26 123 ± 48 0.393
Albumin (mg/dl) 40 ± 3 40 ± 3 38 ± 5 0.284
Platelet count (x109/l) 277 ± 66 285 ± 74 205 ± 60 0.011
Fasting glucose (mmol/l) 5.3 ± 0.9 6.6 ± 2.4 8.9 ± 3.2 < 0.001
Fasting insulin  (mmol/l) 17.2 ± 11.2 27.0 ± 20.8 34.7 ± 19.0 0.003
HOMA-IR* 4.2 ± 3.0 8.4 ± 11.1 15.8 ± 13.5 0.002
Triglycerides* (mmol/l) 1.5 ± 0.7 1.9 ± 1.1 1.4 ± 0.6 0.082
Total cholesterol (mmol/l) 5.2 ± 1.1 4.8 ± 1.2 4.3 ± 1.4 0.055
LDL-cholesterol (mmol/l) 3.2 ± 1.0 2.7 ± 1.0 2.4 ± 0.8 0.014










Control NAFLD F0-2 NAFLD F3/4 P value
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Table 2: Association between serum bile acids and advanced (F3/4) fibrosis in NAFLD (n=120).
Serum Bile Acid OR 95% CI P 
value
OR 95% CI P 
value
Univariate Analysis Multivariate Analysis*
Total Bile Acid Level 2.81 1.35-5.87 0.006 3.49 1.22-9.99 0.02
Total primary unconjugated 
BAs
1.09 0.67-1.76 0.72
    CA 0.80 0.47-1.32 0.40
    CDCA 1.01 0.62-1.65 0.97
Total primary conjugated Bas 2.76 1.40-5.45 0.003 3.99 1.37-11.57 0.01
    GCA 2.09 1.24-3.52 0.006 2.41 1.15-5.05 0.02
    GCDCA 2.92 1.39-6.13 0.005 4.68 1.37-16.02 0.01
Total Secondary unconjugated 
BAs
2.30 1.01-5.23 0.048 1.70 0.70-4.12 0.24
     DCA 2.58 1.04-6.18 0.03 1.72 0.67-4.39 0.26
Total Secondary conjugated 
BAs
3.22 1.41-7.37 0.006 4.08 1.35-12.33 0.01
    GDCA 3.08 1.45-6.53 0.003 3.34 1.31-8.54 0.01
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Table 3: Association between stool bile acids and advanced (F3/4) fibrosis in NAFLD (n=122).
Faecal Bile Acids OR 95% CI P value OR 95% CI P value
Univariate Analysis Adjusted Analysis
Total BAs 3.86 1.46-10.19 0.006 3.19 1.04-9.78 0.04
Total primary BAs 1.40 0.99-1.96 0.05 1.32 0.87-2.00 0.2
Total primary 
unconjugated BAs
1.33 0.98-1.80 0.06 - - -
        CA 1.31 0.99-1.73 0.06 - - -
Total Secondary BAs 4.66 1.52-14.1 0.006 3.38 1.08-10.5
7
0.04
Total Secondary 4.68 1.54-14.22 0.006 3.38 1.08-10.5 0.04
unconjugated BAs 4
        DCA 4.18 1.42-12.30 0.01 3.06 1.04-9.00 0.04
        LC 2.89 1.19-7.04 0.02 2.00 0.89-4.50 0.09
Footnote: Using logistic regression with bile acids log-transformed. *Adjusted for age, diabetes 
and total cholesterol. CA=cholic acid, DCA=deoxycholic acid, LC=lithocholic acid.
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Table 4.  Association between gut microbial taxa (family level) and alcohol intake (n=89).




P value Spearman 
rho
P value
Actinomycetaceae -0.09 0.4 -0.9 0.4
Bacteroidaceae 0.07 0.5 0.07 0.5
Bacteroidales_other 0.36 <0.001 0.37 <0.001
Barnesiellaceae 0.14 0.2 0.07 0.5
Coriobacteriaceae -0.05 0.7 -0.05 0.6
Lachnospiraceae -0.22 0.04 -0.22 0.04
Odoribacteraceae 0.01 0.9 0.01 0.9
Rickenellaceae -0.06 0.6 0.17 0.1
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Figure Legends
Figure 1. The distribution of bile acids in control patients, patients with NAFLD and no/minimal 
fibrosis and patients with NAFLD and advanced fibrosis, in serum ( figure 1A, n=120) and stool 
(figure 1B, n=122).
Footnote: Median and interquartile range presented. * p<0.05 comparing with controls, # p<0.05 
comparing with NAFLD F0-2 using Kruskall-Walis test with Bonferroni adjustment.  CA=cholic 
acid, CDCA= chenodeoxycholic acid, GCA=glycocholic acid, GCDCA=glycochenodeoxycholic acid, 
DCA=deoxycholic acid, GDCA=glycodeoxycholic acid, LC=lithocholic acid.
Figure 2 (A-C).  The proportion of serum primary conjugated bile acids, glycocholic acid and 
glycodeoxycholic acid increased significantly between controls, NAFLD with F0-2 and NAFLD with 
F3/4 (n=120).
Footnote: Percentage with standard deviation presented. Comparisons performed using one-way 
ANOVA with Bonferroni adjustment for post-hoc comparisons. * p<0.05 vs. control; # p<0.05 vs 
NAFLD F0-2.
Figure 3.  Abundance of gut microbial taxa (family level) among non-NAFLD controls, NAFLD 
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Footnote:  Differences in gut taxa between patient groups analysed using Kruskall-Walis test 
with Bonferroni correction, *p<0.05.  Blue heat map demonstrates median relative abundance 
of taxa in each patient group. Bacteroidales_Other represents an unidentified family within the 
Bacteroidales order.
Figure 4.  Association between abundance of gut microbial taxa (family level) and serum 
(n=120) and faecal (n=122) bile acid concentrations.  
Footnote:  Association between gut taxa and serum and stool bile acid concentrations analysed 
using spearman correlation with Bonferroni adjustment for multiple comparisons, *p<0.05. 
Red/green heat map demonstrates spearman correlation co-efficient between relative 











Figure 1. The distribution of bile acids in control patients, patients with NAFLD and no/minimal 
fibrosis and patients with NAFLD and advanced fibrosis, in serum (Figure 1A, n=120) and stool 
(Figure 1B, n=122). 
 
Footnote: Median and interquartile range presented. * p<0.05 comparing with controls, # 
p<0.05 comparing with NAFLD F0-2 using Kruskall-Walis test with Bonferroni adjustment.  
















Figure 2 (A-C).  The proportion of serum primary conjugated bile acids, glycocholic acid and 
glycodeoxycholic acid increased significantly between controls, NAFLD with F0-2 and NAFLD 
with F3/4 (n=120). 
 
 
Footnote: Percentage with standard deviation presented. Comparisons performed using one-
way ANOVA with Bonferroni adjustment for post-hoc comparisons. * p<0.05 vs. control; # 











Figure 3.  Abundance of gut microbial taxa (family level) among non-NAFLD controls, NAFLD with no/minimal fibrosis and NAFLD 
with advanced fibrosis (n=122).   
 
Footnote:  Differences in gut taxa between patient groups analysed using Kruskall-Walis test with Bonferroni correction, *p<0.05.  
Blue heat map demonstrates median relative abundance of taxa in each patient group. Bacteroidales_Other represents an 















Figure 4.  Association between abundance of gut microbial taxa (family level) and serum and faecal bile acid concentrations.   
 
 
Footnote:  Association between gut taxa and serum and stool bile acid concentrations analysed using spearman correlation with 
Bonferroni adjustment for multiple comparisons, *p<0.05. Red/green heat map demonstrates spearman correlation co-efficient 
between relative abundance of each taxa and concentration of bile acid. 
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
 
 
 
 
 
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
